Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Reshaping Dosage Forms

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

Frontrunners in Bispecific Antibodies

Topic

Articles

Porvair has developed a 2-ml 96 round-well deep-well plate that enables scientists to use the full 2.00 ml well capacity.

Application Optimized Microplate Products from Porvair Sciences

GEA’s tableting technologies include a unique system that independently and simultaneously measures and controls both tablet weight and hardness, and a weight control system that provides increased sensitivity at lower forces.

GEA Highlights New Developments in Compression, Containment, and Continuous Processing

PSL has developed a dispensary isolator with a contained drum hoist mechanism for highly potent API production.

PSL Exhibits Nano-Containment Technology

This latest model is said to offer higher output and more efficient dedusting process.

Pharma Technology Inc. Debuts New PharmaFlex iSeries Deduster

GEA will showcase the ConsiGma continuous coater and the PCMM (portable, continuous, miniature, and modular) manufacturing technology platform for continuous production of oral solid dosage forms.

GEA Runs Live Demonstrations of Continuous Manufacturing Solutions

Randi Hernandez was science editor at Pharmaceutical Technology from September 2014 to May 2017.

In a Citizen Petition to FDA, AbbVie calls the current biosimilar labeling practices “legally unsound.”

Biosimilar Labeling Practices Under Fire in New Citizen Petition

Successful drug delivery via a dry powder inhaler is determined by the API physicochemical properties, the formulation composition and process, the device and operating conditions, the patient–device relationship, the environmental variables, and ultimately, patient compliance.

Developing an Orally Inhaled Dry Powder Formulation—A Complex Itinerary and a Technological Challenge

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

Biopharma companies on both sides of the Atlantic ship more of their assay testing to outside service providers.

Another In-House Operation Gets Outsourced

Pharmaceutical Technology spoke with David Fitzhenry about the costs of specialty drugs.

Industry Expert Q&A with David Fitzhenry

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

PAT holds the key to real-time quality assurance and consistent product quality in pharmaceutical manufacturing.